tiprankstipranks
Akums Drugs and Pharmaceuticals Limited (IN:AKUMS)
:AKUMS
India Market
AKUMS
Akums Drugs and Pharmaceuticals Limited
RESEARCH TOOLSreports
Holding IN:AKUMS?
Track your performance easily

Akums Drugs and Pharmaceuticals Limited (AKUMS) Stock Price & Analysis

0 Followers

AKUMS Stock Chart & Stats


AKUMS FAQ

What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹527.00 and its highest was ₹1174.85 in the past 12 months.
    What is Akums Drugs and Pharmaceuticals Limited’s market cap?
    Currently, no data Available
    When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
    Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Aug 25, 2025 which is in 206 days.
      How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
      Akums Drugs and Pharmaceuticals Limited released its earnings results on Nov 09, 2024. The company reported ₹4.259 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.259.
        Is Akums Drugs and Pharmaceuticals Limited overvalued?
        According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Akums Drugs and Pharmaceuticals Limited pay dividends?
          Akums Drugs and Pharmaceuticals Limited does not currently pay dividends.
          What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
          Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
          Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
            What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
            Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹4.259 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
              Currently, no hedge funds are holding shares in IN:AKUMS
              ---

              AKUMS Stock 12 Month Forecast

              Average Price Target

              ₹710.00
              ▲(28.88% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"616":"₹616","679":"₹679","742":"₹742","805":"₹805","868":"₹868"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":710,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹710.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":710,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹710.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":710,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹710.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[616,679,742,805,868],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,633.5,639.3846153846154,645.2692307692307,651.1538461538462,657.0384615384615,662.9230769230769,668.8076923076923,674.6923076923077,680.5769230769231,686.4615384615385,692.3461538461538,698.2307692307693,704.1153846153846,{"y":710,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,633.5,639.3846153846154,645.2692307692307,651.1538461538462,657.0384615384615,662.9230769230769,668.8076923076923,674.6923076923077,680.5769230769231,686.4615384615385,692.3461538461538,698.2307692307693,704.1153846153846,{"y":710,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,633.5,639.3846153846154,645.2692307692307,651.1538461538462,657.0384615384615,662.9230769230769,668.8076923076923,674.6923076923077,680.5769230769231,686.4615384615385,692.3461538461538,698.2307692307693,704.1153846153846,{"y":710,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":791.7,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":832.65,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":867.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":841.1,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":617.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              Aurobindo Pharma Ltd
              Cipla Ltd
              Dr. Reddy's Laboratories Ltd.
              Lupin Limited
              Sun Pharmaceutical Industries Limited

              Best Analysts Covering AKUMS

              1 Year
              Abdulkader PuranwalaICICI Securities
              1 Year Success Rate
              0/1 ratings generated profit
              0%
              1 Year Average Return
              -7.70%
              initiated a buy rating 11 days ago
              Copying Abdulkader Puranwala's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -7.70% per trade.
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis